Dean of Medicine
Address:
Centre for Molecular Medicine
Clinical Research Centre, Level 7
Ninewells Hospital & Medical School
Dundee
DD1 9SY
Phone Number:
+(44) 01382 632456
Email Address:
a.d.morris@dundee.ac.uk
Biography
Andrew Morris is the Professor of Medicine and Director of the Medical Research Institute at the University of Dundee. He leads a research team that uses informatics to study the epidemiological and molecular aetiological basis of diabetes and its complications. He also has a major interest in the use of informatics to support research quality improvement and inter-disciplinary patient care nationally. He leads the DARTS research study, has published over 200 original papers and has attracted over £20million in peer reviewed grant funding.
He is the principal investigator on many clinical studies of new therapeutics of diabetes as well as genetics of diabetes, including the Wellcome Trust United Kingdom Case Control Collection for Type 2 Diabetes that has recruited 20,000 individuals and Generation Scotland, a study of the genetic health in 50,000 Scots. He was awarded the RD Lawrence Award by Diabetes UK in 2003, the Saltire Society Scottish Science Award in 2005 and is a Fellow of the Royal Society of Edinburgh, Scotland’s national academy of science and letters, and Fellow of the Academy of Medical Sciences.
He was appointed by the Minister for Health and Community Care to be Lead Clinician for Diabetes in Scotland (2002-2006) and led a national programme of quality improvement in diabetes care. He is a Governor of the Health Foundation. Since 2010 he has been Convener of the Scottish Academic Health Science Collaboration.
Research
My translational research programme links the epidemiology, informatics, clinical trials and genetics of diabetes. I am/have been the Principal Investigator (PI) of four Programme Grants: (i)The Wellcome Trust Functional Genomics UK Collection for Type 2 Diabetes (2004) – led by Dundee, with Oxford, Cambridge, Mayo Clinic; (ii) the £7.4M CSO Generation Scotland: Family Health Study (2005), that is recruiting 50,000 family members in Scotland for the genetic study of common diseases; (iii) Dundee PI of the £50M Translational Medicine Research Collaboration, a unique pan-Scotland collaboration between NHS Scotland, Universities Scottish Enterprise and Pfizer; (iv) The £3.6M Wellcome Trust Scottish Health Informatics Programme SHIP.
This ambitious 3-year programme will create a Scotland-wide research platform for the collation, management, dissemination and analysis of Electronic Patient Records (EPRs). The programme brings together the Information Services Division (ISD) of NHS Scotland and an inter-disciplinary group of academics from medical and social science background. (2009-2012). Since 1997 I have supervised seven MD/PhD students, and seven postdoctoral fellows.
Publications
- Cunningham S, McAlpine R, Leese G, Brennan G, Sullivan F, Connacher A, Waller A, Boyle DI, Greene S, Wilson E, Emslie-Smith A, Morris AD. Using web technology to support population-based diabetes care. J Diabetes Sci Technol. 2011 May 5(3):523-34.
- Govan L, Wu O, Briggs A, Colhoun HM, McKnight JA, Morris AD, Pearson DW, Petrie JR, Sattar N, Wild SH, Lindsay RS; on behalf of the Scottish Diabetes Research Network Epidemiology Group. Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2011 54(8):2000-8.
- Walker JJ, Livingstone SJ, Colhoun HM, Lindsay RS, McKnight JA, Morris AD, Petrie JR, Philip S, Sattar N, Wild SH; on behalf of the Scottish Diabetes Research Network Epidemiology Group. Effect of Socioeconomic Status on Mortality Among People With Type 2 Diabetes: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetes Care. 2011 34(5):1127-32.
- The GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group & The Wellcome Trust Case Control Consortium 2Zhou K, Bellenguez C, Spencer CCA, Bennett AJ, Coleman RL, Tavendale R, Hawley SA, Donnelly LA, Schofield C, Groves CJ, Burch L, Carr F, Strange A, Freeman C, Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin A, Craddock N, Deloukas P, Dronov S, Duncanson A, Edkins A, Gray E, Hunt A, Jankowski J, Langford C, Markus HS, Mathew CG, Plomin R, Rautanen A, Sawcer SJ, Samani NJ, Trembath R, Viswanathan AC, Wood NW, MAGIC Investigators, Harries LW, Hattersley AT, Doney ASF, Colhoun H, Morris AD, Sutherland C, Hardie DG, Peltonen L, McCarthy MI, Holman RR, Palmer CNA, Donnelly P, Pearson ER. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nature Genetics Volume: 43, Pages: 117–120 Year published: (2011).
- De Silva NM, Freathy RM, Palmer TM, Donnelly LA, Luan J, Gaunt T, Langenberg C, Weedon MN, Shields B, Knight BA, Ward KJ, Sandhu MS, Harbord RM, McCarthy MI, Smith GD, Ebrahim S, Hattersley AT, Wareham N, Lawlor DA, Morris AD, Palmer CN, Frayling TM. Mendelian Randomization Studies Do Not Support a Role for Raised Circulating Triglyceride Levels Influencing Type 2 Diabetes, Glucose Levels, or Insulin Resistance. Diabetes. 2011 60(3): 1008-18.
- Ellis JD, Zvandasara T, Leese G, McAlpine R, Macewen CJ, Baines PS, Crombie I, Morris AD; For the DARTS/MEMO Collaboration. Clues to duration of undiagnosed disease from retinopathy and maculopathy at diagnosis in type 2 diabetes: a cross-sectional study. Br J Ophthalmol. 2011 95(9):1229-33.
- Donnelly LA, Doney AS, Tavendale R, Lang CC, Pearson ER, Colhoun HM, McCarthy MI, Hattersley AT, Morris AD, Palmer CN. Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS Study. Clin Pharmacol Ther. 2011 89(2):210-6.
- Logie L, Ruiz-Alcaraz AJ, Schofield CJ, Hundal HS, Feuerstein GZ, Brady JD, Crowther D, Tommasi AM, Grierson CE, Shepherd B, Morris AD, Hansen MK, Pearson E, Sutherland C. Generation, validation and humanisation of a novel insulin resistant cell model. Biochem Pharmacol. 2010 80(7):1042-9.
- Evans JM, Doney AS, Alzadjali MA, Ogston SA, Petrie JR, Morris AD, Struthers AD, Wong AK, Lang CC. Effect of Metformin on Mortality in Patients With Heart Failure and Type 2 Diabetes Mellitus. Am J Cardiol. 2010 106(7):1006-1010.
- Barnett KN, Ogston SA, McMurdo ME, Morris AD, Evans JM. A 12-year follow-up study of all-cause and cardiovascular mortality among 10,532 people newly diagnosed with Type 2 diabetes in Tayside, Scotland. Diabet Med. 2010 27(10):1124-1129.
- Palmer CN, Kimber CH, Doney AS, Proia AS, Morris AD, Gaetani E, Quarta M, Smith RC, Pola R. Combined Effect of Inflammatory Gene Polymorphisms and the Risk of Ischemic Stroke in a Prospective Cohort of Subjects with Type 2 Diabetes: A Go-DARTS Study. Diabetes. 2010 59(11):2945-8.
- Burch LR, Donnelly LA, Doney AS, Brady J, Tommasi AM, Whitley AL, Goddard C, Morris AD, Hansen MK, Palmer CN. Peroxisome Proliferator-Activated Receptor-{delta} Genotype Influences Metabolic Phenotype and May Influence Lipid Response to Statin Therapy in Humans: A Genetics of Diabetes Audit and Research Tayside Study. J Clin Endocrinol Metab. 2010 95(4):1830-7.
- Zhou K, Donnelly L, Burch L, Tavendale R, Doney AS, Leese G, Hattersley AT, McCarthy MI, Morris AD, Lang CC, Palmer CN, Pearson ER Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther. 2010 87(1):52-6.
- Flynn RW, Bonellie SR, Jung RT, Macdonald TM, Morris AD, Leese GP.Serum Thyroid-Stimulating Hormone Concentration and Morbidity from Cardiovascular Disease and Fractures in Patients on Long-Term Thyroxine Therapy. J Clin Endocrinol Metab. 2010:95(1):186-93.
- Guthrie B, Morris AD, Emslie-Smith A. Which people with type 2 diabetes achieve good control of intermediate outcomes? Population database study in a UK region. Diabetic Medicine 2009; 26(12):1269-76.
- Salanti G, Southam L, Altshuler D, Ardlie K, Barroso I, Boehnke M, Cornelis MC, Frayling TM, Grallert H, Grarup N, Groop L, Hansen T, Hattersley AT, Hu FB, Hveem K, Illig T, Kuusisto J, Laakso M, Langenberg C, Lyssenko V, McCarthy MI, Morris AD, Palmer CN, Payne F, Platou CG, Scott LJ, Voight BF, Wareham NJ, Zeggini E, Ioannidis JP. Underlying Genetic Models of Inheritance in Established Type 2 Diabetes Associations. Am J Epidemiol. 2009 170(5):537-45
- Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 2009; 32(9):1620-1625.
- Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G, Hattersley AT, McCarthy MI, Morris AD, Palmer CN, Pearson ER. Reduced function SLC22A1 polymorphisms encoding Organic Cation Transporter 1 (OCT1) and glycaemic response to metformin: A Go-DARTS study. Diabetes 2009 58(6):1434-9.
- Macleod AK, Liewald DC, McGilchrist MM, Morris AD, Kerr SM, Porteous DJ. Some principles and practices of genetic biobanking studies. Eur Respir J. 2009 33(2):419-25.
- Donnelly LA, Doney AS, Hattersley AT, Morris AD, Pearson ER. The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes. Diabet Med. 2006 23(2):128-33.
- Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005 330(7503):1304-5.
- A D Morris, DIR Boyle, AD McMahon, SA Greene, TM MacDonald, RW Newton. Adherence to insulin therapy, glycaemic control and ketoacidosis in insulin-dependent diabetes. DARTS/MEMO Collaboration. Lancet, 1997 22; 350(9090):1505-10.
- A D Morris, DIR Boyle, R MacAlpine, A Emslie-Smith, RT Jung, RW Newton, TM MacDonald. The Diabetes Audit and Research in Tayside Scotland (DARTS) Study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 1997 30;315(7107):524-8.
- Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JR, Elliot KS, Lango H, Rayner NW, Shields B, Harries LW, Barrett JC, Ellard S, Groves CJ, Knight B, Patch AM, Ness AT, Ebrahim S, Lawloe DA, Ring SM, Ben-Sholmo Y, Jarvelin MR, Sovio U, Bennett AJ, Melzer D, Ferrucci L, Loos RJ, Barroso I, Wareham NJ, Karpe F, Owen KR, Cardon LR, Walker M, Hitman Ga, Palmer CN, Doney AS, Morris AD, Davey-Smith G, Hattersley AT, McCarthy MI. The Wellcome Trust Case Control Consortium: A common Variant in the FTO Gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007 11:316(5826):889-94.
Conferences
- Wellcome Trust Cohort Studies North-South Networking Meeting, Arusha, Tanzania. 6-7 January 2008.
- TMRC Annual Conference, Glasgow. 4-5 February 2008.
- ITMAT 2008 International Symposium (Institute for Translational Medicine & Therapeutics), University of Pennsylvania. 14-15 April 2008.
- Australian Clinical Network Collaborative - “Implementing through influence Networks and translational research”/ Implementation of a National Diabetes Framework: the Key Role of Networks”,Bendigo, Melbourne, Australia. 30 April 2008.
- Rural Health Conference 2008 Keynote presentation – “Options and opportunities in an epidemic of diabetes” Bendigo, Melbourne. 1 May 2008.
- Scottish Society of Physicians “50th Anniversary” Annual Scientific Meeting, Glasgow – “50 years of diabetes mellitus: a nationwide approach to care and research”. 26 September 2008.
- CAD International Conference, Mumbai, India. 5 October 2008.
- Genomic Medicine, Science and Technology Sub-Committee II, House of Lords. 15 October 2008.
- SCIMP Conference, Dunblane – “Options and Opportunities for eHealth”. 4 November 2008.
- Imperial College London Diabetes Centre, Abu Dhabi. 10-11 November 2008
- UKTI/SDI Leadership Forum on Diabetes, Tokyo, Japan – “Informatics supporting Genomic Science”. February 2009.
- Diabetes UK, SECC Glasgow “The Changing Face of Diabetes: Epidemiology UK & Worldwide”. 11 March 2009.
- CLS Annual Symposium, Ninewells Guest Lecture, Crieff – “Gearing an entire country for translational research”. 14 March 2009.
- 3rd International Congress on Pre-Diabetes and the Metabolic Syndrome, Nice, France. 31 March 2009.
- King's College London Graduate Research Showcase Event. Keynote lecture “Options and opportunities in an epidemic of diabetes. 23 July 2009.
- International Conference of Coronary Artery Disease & Diabetes, Mumbai, India. 9-11 October 2009.
- MRC Epidemiology Resource Centre & Epidemiology Unit Scientific QQR Reviews (Quinquennial Review Panel), London. 12 October 2009.
- Invited Guest Lecture 50th Anniversary of WHO ACHR One Day Scientific Symposium, Panama City. 11-12 November 2009.
- Invited Plenary Speaker ADEGS Conference, Dundee. 21 January 2010.
- Expert Workshop on Metformin and Cancer, Lyon France. 29-31 January 2010.
- Seminar at the Dasman Institute, Kuwait. 11-12 February 2010.
- The Health Foundation, International Quality Improvement Exchange (IQIE), Scotland. 4-6March 2010.
- Network to Network 2010. Australasian Conference on Clinical Networks, Melbourne, Australia. 17–19 March 2010.
- Diabetes in Scotland 2010, Herriot Watt University, Edinburgh. 23 March 2010.
- The 12th European Congress of Endocrinology 2010 ECE, Prague, Czech Republic “Cardiovascular benefit of metformin in adults with type 2 diabetes”. 24–28 April 2010.
- Tayside Diabetes MCN Patient and Carer Event, Dundee. 8 May 2010.
- Richard Doll Seminar Series, University of Oxford “Gearing an entire country for diabetes research: a view from the North”. 12 May 2010.
- The Scottish Association of NHS Medical Directors Annual Conference, Dunkeld “Informatics: the catalyst for 21st Century Quality Care?” 13-14 May 2010.
- Advanced Diabetes Postgraduate Course, Bute Medical School, University of St Andrews "The Diabetes epidemic - can we avoid a human catastrophe?" 17 May 2010.
- Diabetes & obesity: getting to the heart of the matter, Royal Society of Edinburgh “Opportunities for translation in an epidemic of diabetes”. 26 May 2010.
- IPRI - University of Dundee Summer School on Epidemiology and Global Health “Options and opportunities in an epidemic of diabetes”. 14 July 2010.
- MRC Routine Health Data Workshop, Royal Institute of British Architects, London “Options and Opportunities for Record Linkage in Scotland”. 24 September 2010.
- ABPI/BIA Innovation Conference, Royal Society of Medicine, London “Collaborative research and initiatives in Scotland. 25 October 2010.
- Annual Symposium – The future of Pharmaceutical Medicine: Industry, Academic and the NHS working together for the patient. Royal College of Physicians, London “They key role of informatics in competitive academic and NHS research”. 19 November 2010.
- Translational Medicine and Therapeutics (TMAT) Scotland/ Launch of the Scottish Clinical Pharmacology and Pathology Programme (SCP3) and the Scottish Translational Medicine and Therapeutics Initiative (STMTI). The Wellcome Auditorium QMRI, Edinburgh. 22 November 2010.
- 9th Annual Meeting: Update on Cardiovascular Disease 2011 - Karolinksa Institutet. Stockholm City Conference Center, Sweden “The rise and rise of Metformin”. 22 January 2011.
- MRC Obesity, Diabetes and Related Metabolic Disorders – Challenges & Opportunities Workshop BIS Conference Centre, London. “Biomedical Informatics as a catalyst for change.” 2 March 2011
- IBIZ March 2011 Stratified Medicine – A Paradigm Shift in Healthcare ExCel, London. “Biomedical Informatics: disruptive technology for stratified medicine?” 10 March 2011.
- Welcome Trust Sanger Institute, Hinxton, Cambridge “Biomedical Informatics: disruptive technology for stratified medicine?” 8 April 2011.
- 3rd Sheffield diabetes Masterclass: achieving best practice, Sheffield. “Options and opportunities in an epidemic of diabetes”. 18 May 2011.
- Scottish Diabetes Research Network Conference, Stirling. “Bioinformatics within GO-DARTS”. 26 August 2011.
- EASD Symposium "Diabetes Care in Europe - striving for excellence", Feira Internacional de Lisboa, Lisbon "Gearing an entire country for diabetes care and research: the Scottish experience". 12–16 September 2011.
- Crick Institute Clinical Translation Strategy Meeting, The Wellcome Trust, London – 17 October 2011.
- ABPI November Conference 2011 – Innovation in Healthcare, Royal Society, London “Collaboration R&D as the foundation of successful joint working”. 3 November 2011.